Literature DB >> 22608362

Cancer care Ontario guideline recommendations for hormone receptor testing in breast cancer.

S Nofech-Mozes1, E T Vella, S Dhesy-Thind, W M Hanna.   

Abstract

Hormone receptor testing (oestrogen and progesterone) in breast cancer at the time of primary diagnosis is used to guide treatment decisions. Accurate and standardised testing methods are critical to ensure the proper classification of the patient's hormone receptor status. Recommendations were developed to improve the quality and accuracy of hormone receptor testing based on a systematic review conducted jointly by the American Society of Clinical Oncology/College of American Pathologists and Cancer Care Ontario's Program in Evidence-Based Care. Evidence-based recommendations were formulated to set standards for optimising immunohistochemistry in assessing hormone receptor status, as well as assuring quality and proficiency between and within laboratories. A formal external review was conducted to validate the relevance of these recommendations. It is anticipated that widespread adoption of these guidelines will further improve the accuracy of hormone receptor testing in Canada.
Copyright © 2012 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22608362     DOI: 10.1016/j.clon.2012.04.005

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  4 in total

Review 1.  Adjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline.

Authors:  O C Freedman; G G Fletcher; S Gandhi; M Mates; S F Dent; M E Trudeau; A Eisen
Journal:  Curr Oncol       Date:  2015-03       Impact factor: 3.677

2.  [Update of the German S3 breast cancer guideline : What is new for pathologists?]

Authors:  A Lebeau; C Denkert; P Sinn; M Schmidt; A Wöckel
Journal:  Pathologe       Date:  2019-03       Impact factor: 1.011

3.  Pathological Diagnosis, Work-Up and Reporting of Breast Cancer 1st Central-Eastern European Professional Consensus Statement on Breast Cancer.

Authors:  Gábor Cserni; Monika Francz; Balázs Járay; Endre Kálmán; Ilona Kovács; Tibor Krenács; Erika Tóth; Nóra Udvarhelyi; László Vass; András Vörös; Ana Krivokuca; Karol Kajo; Katarína Kajová Macháleková; Janina Kulka
Journal:  Pathol Oncol Res       Date:  2022-06-27       Impact factor: 2.874

Review 4.  Assessment of estrogen receptor low positive status in breast cancer: Implications for pathologists and oncologists.

Authors:  Nicola Fusco; Moira Ragazzi; Elham Sajjadi; Konstantinos Venetis; Roberto Piciotti; Stefania Morganti; Giacomo Santandrea; Giuseppe Nicolò Fanelli; Luca Despini; Marco Invernizzi; Bruna Cerbelli; Cristian Scatena; Carmen Criscitiello
Journal:  Histol Histopathol       Date:  2021-09-29       Impact factor: 2.303

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.